REH/iRFP stable cell line

REH/iRFP cells are derived from the human B-cell acute lymphoblastic leukemia (ALL) cell line REH by stably integration of a constitutive miRFP670 stably expression construct. REH cells are used to study the biology of B-ALL, including signaling pathways, cell proliferation, and apoptosis, as well as test new therapeutic approaches. REH cells can be used to identify suitable antigen targets for CAR-T therapies. Common targets for B-cell malignancies include CD19 and CD22, both of which are expressed on REH cells. REH/iRFP cells stably express miRFP670, can be used for in vitro assays and in vivo imaging.